Thus, identification of these immune checkpoint regulators, such as programmed cell death protein 1 (PD-1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and other inhibitory signaling, has created a new vision for cancer immunotherapy (131, 132). Here, PDCD1 is linked to cancer.